Not Yet Recruiting
PHASE3
INTERVENTIONAL
NCT07271251
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of the study is to find out if the new tablet formulation oral semaglutide D is equally safe and effective as the approved oral semaglutide for treating Japanese people with type 2 diabetes. Participants will receive either oral semaglutide D (the treatment being tested) or oral semaglutide (the comparator); which treatment a participant gets is decided by chance. Oral semaglutide is an approved tablet (a treatment used as a comparator), while oral semaglutide D is described as the new tablet formulation being tested in this study. The study will last approximately 27 weeks.
Interventions
Name:
Oral semaglutide
Type:
DRUG
Description:
Semaglutide will be administered orally once daily.
Primary Outcomes
Measure:
Change in glycated haemoglobin (HbA1c).
TimeFrame:
From baseline (week 0) to end of treatment (week 20)
Description:
Measured in percentage (%)-point.
Trial Information
NCT ID
NCT07271251
Status
Not Yet Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025